Hector Albert-Gasco

Hector Albert-Gasco

Auto-generated profile, based on publicly available information

Hector Albert-Gasco

UK Dementia Research Institute and Department of Clinical Neurosciences, University of Cambridge , Cambridge CB2 0AH , UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2023 in Brain
Verified
Journal Article
Open access
PDF file
HAHector Albert-Gasco
Hector Albert-Gasco
HSHeather L Smith
Heather L Smith
BABeatriz Alvarez-Castelao
Beatriz Alvarez-Castelao
DSDean Swinden
Dean Swinden
MHMark Halliday
Mark Halliday
GMGiovanna R Mallucci
Giovanna R Mallucci
The unfolded protein response (UPR) is rapidly gaining momentum as a therapeutic target for protein misfolding neurodegenerative diseases, in which its overactivation results in sustained translational repression leading to synapse loss and neurodegeneration. In mouse models of these disorders, from Alzheimer’s to prion disease, modulation of the pathway—including by the licensed drug, trazodone—restores global protein synthesis rates with profound neuroprotective effects. However, the precise nature of the translational impairment, in particular the specific proteins affected in disease, and their response to therapeutic UPR modulation are poorly understood. We used non-canonical amino acid tagging (NCAT) to measure de novo protein synthesis in the brains of prion-diseased mice with and without trazodone treatment, in both whole hippocampus and cell-specifically. During disease the predominant nascent proteome changes occur in synaptic, cytoskeletal and mitochondrial proteins in both hippocampal neurons and astrocytes. Remarkably, trazodone treatment for just 2 weeks largely restored the whole disease nascent proteome in the hippocampus to that of healthy, uninfected mice, predominantly with recovery of proteins involved in synaptic and mitochondrial function. In parallel, trazodone treatment restored the disease-associated decline in synapses and mitochondria and their function to wild-type levels. In conclusion, this study increases our understanding of how translational repression contributes to neurodegeneration through synaptic and mitochondrial toxicity via depletion of key proteins essential for their function. Further, it provides new insights into the neuroprotective mechanisms of trazodone through reversal of this toxicity, relevant for the treatment of neurodegenerative diseases via translational modulation.

28 October 2018 in Brain Structure and Function
Verified
Journal Article
Closed access
PDF file
HAHector Albert-Gasco
Hector Albert-Gasco
Sandra Sánchez-SarasúaSandra Sánchez-Sarasúa
Sandra Sánchez-Sarasúa
SMSherie Ma
Sherie Ma
CGCristina García-Díaz
Cristina García-Díaz
AGAndrew L. Gundlach
Andrew L. Gundlach
Francisco Olucha-BordonauFrancisco Olucha-Bordonau
Francisco Olucha-Bordonau

6 June 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
HAHector Albert-Gasco
Hector Albert-Gasco
HSHeather L. Smith
Heather L. Smith
BABeatriz Alvarez-Castelao
Beatriz Alvarez-Castelao
DSDean Swinden
Dean Swinden
MHMark Halliday
Mark Halliday
GMGiovanna R Mallucci
Giovanna R Mallucci
The unfolded protein response (UPR) is rapidly gaining momentum as a therapeutic target for protein misfolding neurodegenerative diseases, in which its overactivation results in sustained translational repression leading to synapse loss and neurodegeneration. In mouse models of these disorders, from Alzheimer’s to prion disease, modulation of the pathway - including by the licensed drug, trazodone - restores global protein synthesis rates with profound neuroprotective effects. However, the precise nature of the translational impairment, in particular the specific proteins affected in disease, and their response to therapeutic UPR modulation are poorly understood. We used non-canonical amino acid tagging (NCAT) to measure de novo protein synthesis in the brains of prion-diseased mice with and without trazodone treatment, in both whole hippocampus and cell-specifically. During disease the predominant translatome changes occur in synaptic, cytoskeletal and mitochondrial proteins in both hippocampal neurons and astrocytes. Remarkably, trazodone treatment for just two weeks largely restored the whole disease translatome in the hippocampus to that of healthy, uninfected mice, predominantly with recovery of proteins involved in synaptic and mitochondrial function. In parallel, trazodone treatment restored the disease-associated decline in synapses and mitochondria and their function to wildtype levels. In conclusion, this study increases our understanding of how translational repression contributes to neurodegeneration through synaptic and mitochondrial toxicity via depletion of key proteins essential for their function. Further, it provides new insights into the neuroprotective mechanisms of trazodone through reversal of this toxicity, relevant for the treatment of neurodegenerative diseases via translational modulation.